Lates News

Recently, the National Medical Products Administration conditionally approved Jiangsu Hengrui Medicine Co., Ltd.'s application for a Category 1 innovative drug, Apple Acid Formatinib Capsules (trade name: Abit). This drug, in combination with Carilituzumab Monoclonal Antibody for injection, is used for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with Bevacizumab Monoclonal Antibody. The approval of this drug provides new treatment options for patients. (National Medical Products Administration)